Plus, 30-year mortgage rates have fallen to their lowest level ever amid coronavirus fears, and an analyst says Gilead’s COVID-19 treatment only has a 50/50 chance, at best, of proving successful.
Read MoreIt is, perhaps, not too surprising that while the rest of the market has been plagued by fear and uncertainty coming from the increasing spread of coronavirus and questions about the efficacy of government responses, there have been a few pockets of opportunity to be had. One of those is in stocks like Gilead Sciences […]
Read MoreBuy Target – $10.75 or better Sell Target – TradersPro Sell Signal BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered […]
Read MoreThe market likely hasn’t seen a bottom yet, but here’s what investors can watch for now.
Read More